<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934360</url>
  </required_header>
  <id_info>
    <org_study_id>BioDyn-15-003</org_study_id>
    <nct_id>NCT02934360</nct_id>
  </id_info>
  <brief_title>TR(ACE) Assay Clinical Specimen Study</brief_title>
  <official_title>Evaluation of the TR(ACE) Assay for the Ability to Aid in Monitoring Disease Progress, Response to Therapy or for Recurrent or Residual Disease for Patients With Previously Diagnosed Cancers (Stage III and IV Lung and Stage IV Breast)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biological Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biological Dynamics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TR(ACE) Assay is a quantitative in vitro diagnostic test run on the TR(ACE) Instrument
      intended for the measurement of high molecular weight human DNA from plasma as an aid to
      monitoring disease progression or response to therapy or recurrent or residual disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to establish the clinical performance of the TR(ACE) Assay. Deltas of serial
      TR(ACE) Assay measurements will be compared to the standard of care physician clinical
      assessment and RECIST 1.1 criteria evaluation relative to the previous visit. Significant
      changes in serial TR(ACE) Assay measurements are hypothesized to correlate with disease
      progression or response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Assessment change</measure>
    <time_frame>Standard of care (approximately every 6 weeks to 3 months) for 6- 9 months</time_frame>
    <description>Standard of care physician's clinical assessment of disease progression or response compared to previous visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RECIST 1.1 criteria</measure>
    <time_frame>Standard of care (approximately every 6 weeks to 3 months) for 6- 9 months</time_frame>
    <description>RECIST 1.1 criteria of subjects from current to previous visit</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Non-small cell Lung Cancer</arm_group_label>
    <description>Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Cancer</arm_group_label>
    <description>Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TR(ACE) Assay Testing</intervention_name>
    <description>Serial plasma testing with TR(ACE) Assay</description>
    <arm_group_label>Non-small cell Lung Cancer</arm_group_label>
    <arm_group_label>Breast Cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma specimens will be collected prospective and tested retrospectively
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Previously diagnosed non-small cell lung cancer subjects undergoing standard of care
        treatment Previously diagnosed breast cancer subjects undergoing standard of care treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-small cell lung: Male or Female Adult patient &gt;= 21 years old

          -  Breast only: Female Adult patient &gt;= 21 years old

          -  Previously diagnosed with one of the following cancers:

        Breast or Non-small Cell Lung

          -  Cancer has progressed to at least Stage III or higher for lung cancer or,

          -  Cancer has progressed to stage IV (metastatic) breast cancer

          -  Participating in standard of care cancer therapy requiring frequent treatments,
             typically intravenous chemotherapy visits (or as determined by the standard of care
             for the particular cancer assessed), of a minimum of three (3) treatment visits
             planned in 9 months from date of enrollment where a clinical assessment will be
             conducted

        Exclusion Criteria:

          -  Physician assessment that obtaining two extra whole blood specimens with minimum
             volume of 5 mL per treatment visit is contraindicated

          -  Stage I and II Non-small Cell Lung Cancer

          -  Stage I through III breast cancer

          -  Pregnant or planning to become pregnant during the course of the study

          -  Unable to obtain informed consent from subject or their legal representative

          -  Life expectancy is less than 9 months

          -  Presence of one or more of the following other chronic diseases

          -  Another type of cancer except for non-melanomatous skin tumors

          -  Autoimmune disease requiring DMARDS or Biologics

          -  Infectious disease requiring prolonged intravenous antibiotics or hospitalization

          -  Renal disease specifically those in End Stage Renal Failure

          -  Recent (&lt; 3 weeks) major trauma or major surgical procedure(s) or radiation therapy
             prior to enrollment in the study

          -  Recent (&lt; 2 months) major occlusive arterial event such as MI or CVA prior to
             enrollment in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kovelman</last_name>
    <role>Study Director</role>
    <affiliation>Biological Dynamics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patsy Folio</last_name>
    <phone>1-240-415-6022</phone>
    <email>patsy.folio@precisionformedicine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Transis Clemons</last_name>
    <phone>1-240-415-6038</phone>
    <email>transis.clemons@precisionformedicine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Cancer Associates for Reseach and Excellence, Inc. (cCare)</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Garcia</last_name>
      <phone>760-452-3909</phone>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>480-735-9035</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>North County Oncology Medical Inc. (North County)</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumiko Kawai</last_name>
      <phone>760-758-5770</phone>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>480-735-9035</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osita Onugha, MD</last_name>
      <phone>310-829-8618</phone>
      <email>osita.onugha@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Osita Onugha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prutha Patel</last_name>
      <phone>407-921-3767</phone>
      <email>prutha@clorene.org</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>480-735-9035</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bond Clinic</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Branca</last_name>
      <phone>863-293-1191</phone>
      <email>nbranca@bondclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Osama Abu Hlalah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Peabody</last_name>
      <phone>812-353-2831</phone>
      <email>blm-clinicalresearch@iuhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffery Allerton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashland Bellefonte Cancer Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Michmer (Lake Huron Medical Center)</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Fisher, RN</last_name>
      <phone>810-216-1185</phone>
      <email>kfisher2@primehealthcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Robert Langolf</last_name>
      <phone>248-747-4383</phone>
      <email>robert.langolf@michmer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anup Lal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunterdon Hematology Oncology</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Singer</last_name>
      <phone>908-237-2330</phone>
      <phone_ext>3</phone_ext>
      <email>ksinger@hhsnj.org</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Waqas Rehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan A Gapilango, RN MSN OCN CCRP</last_name>
      <phone>732-557-8239</phone>
      <email>jonathan.gapilango@rwjbh.org</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Marx</last_name>
      <phone>631-675-5143</phone>
      <email>dmarx@nycancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Ackler</last_name>
      <phone>215-456-8295</phone>
      <email>acklerj@einstein.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>William Tester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnMed</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AnMed Health Oncology Research Office</last_name>
      <phone>864-512-4650</phone>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>John E Doster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Tibbs</last_name>
      <phone>865-934-2676</phone>
      <email>ktibbs@biomed-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tracy Dobbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Hematology Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perla Lopez</last_name>
      <phone>903-595-7041</phone>
      <email>plopez@hopecancertexas.com</email>
    </contact>
    <contact_backup>
      <last_name>Patsy Folio</last_name>
      <phone>1-240-415-6022</phone>
      <email>patsy.folio@precisionformedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Arielle Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>cell free DNA</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Following direct de novo submission, data will be summarized in decision summary and package insert</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

